Updates. Go to this page for links to updates on 2004 chemotherapy
studies and also a link to 2005 updates. These are in easy to read
table format. As new studies are published, their data will also be added on
the update page.
and Mitoxantrone combinations for 2nd line chemotherapy, February 2007.
Combined Hormonal Ablation/Chemotherapy
for High Risk Prostate Cancer. March 2002.
A Patient's Perspective on Chemotherapy - Part 1
A Patient's Perspective on
Chemotherapy - Part 2
for HRPC - Part 3. A Patient's Review of ASCO 2001 and Current Journal
Abstracts. 12 May 2001.
Can Chemotherapy Extend Survival for Hormone Refractory
Prostate Cancer Patients?
A Patients Perspective, February 2002. This
paper outlines sequential chemotherapies.
-- Leukine, Retinoids and Thalidomide for Extending the Off Period. This
paper discusses a possible way of reducing the side effects of
chemotherapy. October 2004.
A patient’s musings about whether our conventional
treatment for advanced prostate cancer with chemotherapy can be modified to
prolong quality survival.
Taxol Combinations Including
Taxol and High Dose Calcitriol. Added April 2006.
Taxol or Taxotere? A
comparison of these two chemotherapy drugs from a patient 'friendliness'
point of view. Bill Aishman March 2003.
AbraxaneTM , albumin nanoparticle paclitaxel
(Taxol). H. Hansen, 2/6/07.
Avastin (Bevacizumab) with Taxotere
(Docetaxel). This paper also includes some information on the phase III
trial of this combination as well as the phase II study where thalidomide was
also added for a double antiangiogenesis combination. Howard Hansen
8 April 2010.
Cabazitaxel. This 2nd line
chemotherapy for HRPC patients failing first line taxotere was approved by the
FDA 17 June 2010.
High Dose Pulsed Calcitriol (HDPC)
plus Taxotere - a ≥ 2nd line chemo treatment. HDPC acting a a chemotherapy
re-sensitizing agent. DN-101/Asentar are also covered on this page. HDPC can
also be used with first line taxotere treatment.
an oral or I-V chemotherapy used as a first line or ≥ 2nd line chemotherapy.
Suitable for low-dose metronomic dosing.
Revlimid (lenalidomide). This
paper covers Revlimid in combination with docetaxel and in combination with
leukine. H. Hansen 12/18/2007.
Gemcitabine (Gemzar) for HRPC.
Single agent gemcitabine and gemcitabine combined with other chemotherapeutic
drugs. Consider for use as a 2nd or 3rd line treatment. Howard Hansen 2/16/08.
Vinorelbine (Navelbine) for HRPC.
Single agent vinorelbine, taxotere plus vinorelbine, emcyt plus vinorelbine,
taxol plus vinorelbine, vinorelbine plus adriamycin, vinorelbine plus emcyt plus
mitoxantrone. Howard Hansen 2/12/08.
Xeloda (Capecitabine) for HRPC.
This paper examines Xeloda by itself and in
combination with taxotere. Howard Hansen 1/5/07.